Document is current
Any future updates will be listed below
-
Authors
Skarbaliene, Jolanta http://orcid.org/0000-0003-3965-7504
Mathiesen, Jesper Mosolff http://orcid.org/0000-0003-4251-4416
Larsen, Bjarne Due http://orcid.org/0000-0001-6769-4682
Thorkildsen, Christian http://orcid.org/0000-0001-9450-6675
Petersen, Yvette Miata http://orcid.org/0000-0002-1643-2137
-
Funding
Funding for this research was provided by:
Zealand Pharma A/S
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 10 March 2023
First Online: 21 March 2023
Declarations
:
: The experimental protocols were performed in accordance with ARRIVE guidelines and were approved by the Zealand Pharma Animal Ethics Council. All procedures involving animals were conducted in accordance with guidelines provided by the Danish Ministry of Justice under a specific license (permission number 2007/561–1373).
: Not applicable.
: The authors are employees and stakeholders (JMM, BDL, CT) or former employees and stakeholders (JS, YMP) of Zealand Pharma A/S. JMM holds an affiliation as associate professor with the University of Copenhagen. BDL and YMP are patent holders of glucagon-like peptide-2 (GLP-2) analogs in association with Zealand Pharma A/S (patent number WO 2006/117565 A3).
